Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 11Terminated 4Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 11INDUSTRY 4NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

cilgavimab and tixagevimab drug combination 1Sodium Chloride 1Janus Kinase Inhibitors 1Interleukin-7 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × COVID-19 × Clear all
NCT04404361 2024-06-05

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

CTI BioPharma

Phase 2 Terminated
200 enrolled 16 charts

COVID-19

NCT04426201 2024-04-11

ILIAD-7-US-O

Revimmune

Phase 2 Terminated
10 enrolled

COVID-19, Lymphopenia

NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

NCT04803227 2022-01-04

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Histogen

Phase 1 Terminated
13 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡